Advances in Hypertension and Diabetes;Temas de actualidad en hipertensión arterial y diabetes

Revista Espanola de Cardiologia Suplementos

Volumn 9, Issue 1, 2009, Pages 14-27

  Mazón Ramos, Pilar ^a   Cordero Fort, Alberto ^b   Quiles Granado, Juan ^b   Guindo Soldevila, Josep ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^c HOSPITAL DE SABADELL   (Spain)

Author keywords

Antihypertensive treatment; Cardiovascular prevention; Glycemic control; Vascular damage

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE PLUS BENAZEPRIL; ANTIDIABETIC AGENT; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIURETIC AGENT; GLICLAZIDE; GLITAZONE DERIVATIVE; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN DERIVATIVE; LOSARTAN; METFORMIN; PERINDOPRIL; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; VALSARTAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALBUMINURIA; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN TREATMENT; KIDNEY DISEASE; MEDICAL SOCIETY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIMARY PREVENTION; RECURRENT DISEASE; RENAL PROTECTION; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 67650976581     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(09)71769-8     Document Type: Article

References (35)

1. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
2. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
3. Flather M.D., Yusuf S., Kober L., Pfeffer M., Hall A., Murray G., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355 (2000) 1575-1581
4. Braunwald E., Domanski M.J., Fowler S.E., Geller N.L., Gersh B.J., Hsia J., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
5. Patel A., MacMahon S., Chalmers J., Neal B., Woodward M., Billot L., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
6. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
7. The telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-83.
8. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008) 547-553
9. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
10. Mancia G., De B.G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. Guías de práctica clínica para el tratamiento de la hypertension arterial 2007. Rev Esp Cardiol 60 (2007) 968.e1-968.e94
11. Bakris G.L., Gaxiola E., Messerli F.H., Mancia G., Erdine S., Cooper-DeHoff R., et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 44 (2004) 637-642
12. Jamerson K.A., Bakris G.L., Wun C.C., Dahlöf B., Lefkowitz M., Manfreda S., et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 17 (2004) 793-801
13. Jamerson K., Weber M.A., Bakris G.L., Dahlöp B., Pitt B., Shi V., et al., The AccoMPLiSH trial investigators. Benazepril plus amlodipine of hydrochlorothiazide for hypertension in high-risk. N Engl J Med 359 (2008) 2417-2428
14. Das R.R., Seshadri S., Beiser A.S., Kelly-Hayes M., Au R., Himali J., et al. Prevalence and Correlates of Silent Cerebral Infarcts in the Framingham Offspring Study. Stroke 39 (2008) 2929-2935
15. Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 (2008) 1887-1898
16. Yusuf S., Diener H.C., Sacco R.L., Cotton D., Ounpuu S., Lawton W.A., et al., The PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359 (2008) 1225-1237
17. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
18. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001) 1033-1041
19. Mostaza J.M., Suarez C., Manzano L., Cairols M., Lopez-Fernandez F., Aguilar I., et al. Sub-clinical vascular disease in type 2 diabetic subjects: relationship with chronic complications of diabetes and the presence of cardiovascular disease risk factors. Eur J Intern Med 19 (2008) 255-260
20. Bertomeu V., Morillas P., González-Juanatey J.R., Quiles J., Guindo J., Soria F., et al. Prevalence and prognostic influence of peripheral arterial disease in patients ≥ 40 years old admitted into hospital following an acute coronary event. Eur J Vasc Endovasc Surg 36 (2008) 189-196
21. Welten G.M., Schouten O., Hoeks S.E., Chonchol M., Vidakovic R., Van Domburg R.T., et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol 5 (2008) 1588-1596
22. Monreal M., Álvarez L., Vilaseca B., Coll R., Suarez C., Toril J., et al. Clinical outcome in patients with peripheral artery disease. Results from a prospective registry (FRENA). Eur J Intern Med 19 (2008) 192-197
23. Fowkes F.G., Murray G.D., Butcher I., Heald C.L., Lee R.J., Chambless L.E., et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300 (2008) 197-208
24. Färbom P., Wahlstrand B., Almgren P., Skrtic S., Lanke J., Weiss L., et al. Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the nordic diltiazem study. Hypertension 52 (2008) 115-122
25. Makino H., Haneda M., Babazono T., Moriya T., Ito S., Iwamoto Y., and INNOVATION Study Group. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res 31 (2008) 657-664
26. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K., and AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358 (2008) 2433-2446
27. American Diabetes Association. Standards of medical care in diabetes -2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
28. Ryden L., Standl E., Bartnik M., Van der Berghe G., Betteridge J., De Boer M.J., et al. Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares. Rev Esp Cardiol 60 (2007) 525.e1-525.e64
29. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
30. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
31. Dluhy R.G., and McMahon G.T. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med 358 (2008) 2630-2633
32. González-Juanatey J.R., Cea L., Bertomeu V., Aznar J., and Representación de los investigadores del estudio VIIDA. Criterios electrocardiográficos de hipertrofia ventricular izquierda y perfil de riesgo cardiovascular en hipertensos. Estudio VIIDA. Rev Esp Cardiol 60 (2007) 148-156
33. Fácila L., González-Juanatey J.R., Cea L., Aznar J., Mazón P., Bertomeu González V., and Representación de los investigadores del estudio VIIDA. Control de las cifras de presión arterial en los pacientes hipertensos con hipertrofia ventricular: estudio VIIDA. Rev Esp Cardiol 60 (2007) 1257-1263
34. Palma J.L., Conget I., Bertomeu V., Ascaso J.F., González-Juanatey J.R., Alegría E., et al. Prevalencia del síndorme metabólico en pacientes con enfermedad cardiovascular en España: estudio CLYDIA. Med Clin (Barc) 128 (2007) 407-413
35. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143-421.